Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free CEROW Stock Alerts

CERo Therapeutics (CEROW) Competitors

$0.0048 0.00 (0.00%)
As of 07/15/2026
Compare

CEROW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for CERo Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat CERo Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
CERo Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTSW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Alpha Tau Medical had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Alpha Tau Medical and 0 mentions for CERo Therapeutics. Alpha Tau Medical's average media sentiment score of 1.87 beat CERo Therapeutics' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the media.

Company Overall Sentiment
Alpha Tau Medical Very Positive
CERo Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Alpha Tau MedicalN/A N/A N/A
CERo Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Tau MedicalN/AN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

Summary

Alpha Tau Medical beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for CERo Therapeutics. Apollomics' average media sentiment score of 1.89 beat CERo Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
CERo Therapeutics Neutral

Summary

Apollomics beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to BioVie?

CERo Therapeutics (NASDAQ:CEROW) and BioVie (NASDAQ:BIVIW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, BioVie had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for CERo Therapeutics. BioVie's average media sentiment score of 1.89 beat CERo Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
BioVie Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

Summary

BioVie beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, Cardio Diagnostics had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for CERo Therapeutics. Cardio Diagnostics' average media sentiment score of 1.87 beat CERo Therapeutics' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Cardio Diagnostics Very Positive
CERo Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$16.57KN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

Summary

Cardio Diagnostics beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEROW vs. The Competition

Export
MetricCERo TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$525.31M$6.96B$12.67B
Dividend YieldN/A3.90%2.68%8.87%
P/E RatioN/A3.1427.1824.05
Price / SalesN/A6,485.30577.75112.08
Price / CashN/A13.1349.2559.89
Price / BookN/A87.9210.786.23
Net IncomeN/A-$96.07M$3.59B$331.94M
7 Day PerformanceN/A-1.81%-1.92%-1.65%
1 Month PerformanceN/A1.35%2.24%-1.03%
1 Year PerformanceN/A55.00%23.85%17.10%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEROW
CERo Therapeutics
N/A$0.00
flat		N/AN/A$0.00N/AN/A8
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/AN/A$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$3.55
+4.4%		N/A+991.2%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.02
+43.6%		N/A-47.0%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.50
-2.0%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CEROW) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel